ARS Pharmaceuticals (SPRY) Other Gross PP&E Adjustments (2021 - 2025)
ARS Pharmaceuticals' Other Gross PP&E Adjustments history spans 5 years, with the latest figure at -$3.3 million for Q4 2025.
- For Q4 2025, Other Gross PP&E Adjustments fell 142.12% year-over-year to -$3.3 million; the TTM value through Sep 2025 reached -$1.7 million, down 34.13%, while the annual FY2025 figure was -$3.3 million, 142.12% down from the prior year.
- Other Gross PP&E Adjustments for Q4 2025 was -$3.3 million at ARS Pharmaceuticals, down from -$1.7 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $70000.0 in Q2 2024 and bottomed at -$5.6 million in Q3 2021.
- The 5-year median for Other Gross PP&E Adjustments is -$1.5 million (2023), against an average of -$1.8 million.
- The largest YoY upside for Other Gross PP&E Adjustments was 117.3% in 2024 against a maximum downside of 4213.79% in 2024.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at -$588000.0 in 2021, then crashed by 299.15% to -$2.3 million in 2022, then grew by 28.97% to -$1.7 million in 2023, then rose by 17.82% to -$1.4 million in 2024, then tumbled by 142.12% to -$3.3 million in 2025.
- Per Business Quant, the three most recent readings for SPRY's Other Gross PP&E Adjustments are -$3.3 million (Q4 2025), -$1.7 million (Q3 2025), and -$2.0 million (Q2 2025).